Demo Almirall 03 (13/44)

Demo Almirall 03Demo Almirall 03 (13/44)Demo Almirall 03 - (1/44)Demo Almirall 03 - (2/44)Demo Almirall 03 - (3/44)Demo Almirall 03 - (4/44)Demo Almirall 03 - (5/44)Demo Almirall 03 - Índice (6/44)Demo Almirall 03 - (7/44)Demo Almirall 03 - (8/44)Demo Almirall 03 - (9/44)Demo Almirall 03 - (10/44)Demo Almirall 03 - (11/44)Demo Almirall 03 - (12/44)Demo Almirall 03 - (13/44)Demo Almirall 03 - (14/44)Demo Almirall 03 - (15/44)Demo Almirall 03 - (16/44)Demo Almirall 03 - (17/44)Demo Almirall 03 - (18/44)Demo Almirall 03 - (19/44)Demo Almirall 03 - (20/44)Demo Almirall 03 - (21/44)Demo Almirall 03 - (22/44)Demo Almirall 03 - (23/44)Demo Almirall 03 - (24/44)Demo Almirall 03 - (25/44)Demo Almirall 03 - (26/44)Demo Almirall 03 - (27/44)Demo Almirall 03 - (28/44)Demo Almirall 03 - (29/44)Demo Almirall 03 - (30/44)Demo Almirall 03 - (31/44)Demo Almirall 03 - (32/44)Demo Almirall 03 - (33/44)Demo Almirall 03 - (34/44)Demo Almirall 03 - (35/44)Demo Almirall 03 - (36/44)Demo Almirall 03 - (37/44)Demo Almirall 03 - (38/44)Demo Almirall 03 - (39/44)Demo Almirall 03 - (40/44)Demo Almirall 03 - (41/44)Demo Almirall 03 - (42/44)Demo Almirall 03 - (43/44)Demo Almirall 03 - (44/44) FEB MAR APR MAY JUN Portfolio Collaborations Purpose Pipeline Major milestones in 2023 Acquisition of the Physiorelax® portfolio in Spain Launch of Ilumetri® in Norway, Sweden and Finland ZeClinics joins Almirall’s innovation hub in Barcelona Launch of Wynzora® in Italy Publication of phase lll data of lebrikizumab in NEJM and BMJ POSITIVE study published in the BMJ Launch of Klisyri® in Belgium Collaboration with the CRG to develop and characterize novel preclinical models for non-melanoma skin cancer Second edition of the AK Global Day Launch of "Nina," a series highlighting the impact of psoriasis on wellbeing €200 MM non pre-emptive share capital increase